Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV, open non-randomized low-intervention study of Zeqmelit

Next Previous
Trial Profile

A phase IV, open non-randomized low-intervention study of Zeqmelit

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Hypersensitivity
  • Focus Therapeutic Use
  • Sponsors AcuCort

Most Recent Events

  • 27 Jan 2025 According to an AcuCort media release, the last patient had completed AcuCort's Phase IV study in November 2024. Subsequently, extensive analysis work has been carried out and a study report has been prepared for scientific articles for publication in leading international scientific journals.
  • 20 Mar 2024 According to an AcuCort media release, 25 allergy patients are enrolled in the study, which is intended to include a total of 50 patients and the results will be published in scientific journals and enhance the product's marketing. Results are expected to be available by the end of 2024
  • 20 Mar 2024 Status changed from not yet recruiting to recruiting, according to an AcuCort media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top